Recurrent respiratory papillomatosis in adults with lower respiratory tract involvement: a retrospective study of the OrphaLung and GETIF networks
- PMID: 39915056
- DOI: 10.1183/13993003.00618-2024
Recurrent respiratory papillomatosis in adults with lower respiratory tract involvement: a retrospective study of the OrphaLung and GETIF networks
Abstract
Background: Recurrent respiratory papillomatosis (RRP) is a rare respiratory disease primarily caused by chronic human papillomavirus (HPV) infection of serotypes 6 and 11. It manifests in childhood (juvenile-onset recurrent respiratory papillomatosis (JoRRP)) and adulthood (adult-onset recurrent respiratory papillomatosis (AoRRP)), leading to progressive obstruction by papillomas in the upper airway and occasionally in the lower respiratory tract (LRT), including the lungs, with a potential for malignant transformation. This study aimed to delineate the characteristics of JoRRP and AoRRP with LRT involvement in adulthood.
Methods: A multicentre French-speaking cohort study was conducted, coupled with a comprehensive literature review of clinical, histological, therapeutic and prognostic features associated with RRP with LRT involvement.
Results: Among the 122 cases of RRP with LRT involvement analysed, 55 (45%) had JoRRP and 67 (55%) had AoRRP. The mean age at diagnosis was 4 years for JoRRP and 54 years for AoRRP. Ear, nose and throat involvement was observed in all JoRRP cases and in 34 AoRRP cases (51%). Lung involvement occurred in 47 JoRRP cases (85%) and in 10 AoRRP cases (15%). Malignant transformation to squamous cell carcinoma in the trachea (n=6) or lung (n=36) was observed in 42 patients (34%). Factors associated with lung involvement included JoRRP, repeated debulking and malignant transformation; the only factor associated with malignant transformation was lung involvement. Overall mortality was 16%, with JoRRP, lung involvement and malignant transformation identified as risk factors for death.
Conclusion: This study highlights the prevalence of lung involvement and malignant transformation in RRP with LRT involvement and advocates for targeted screening measures and preventive therapeutic strategies.
Copyright ©The authors 2025. For reproduction rights and permissions contact permissions@ersnet.org.
Conflict of interest statement
Conflict of interest: C. Fournier declares personal fees from Olympus France for organising education sessions; and from Ambu, TSC Endovision and Pentax for consultancy. A. Bourdin declares unrestricted grants to their institution from AstraZeneca and GlaxoSmithKline; participation on advisory boards for AstraZeneca, GlaxoSmithKline, Sanofi and Chiesi; participation on a data safety monitoring board for AB Science; and support for attending congresses from AstraZeneca, GlaxoSmithKline and Sanofi. R. Borie declares consulting fees from Boehringer Ingelheim, Ferrer and Sanofi; and payment or honoraria, and support for attending meetings and/or travel, from Boehringer Ingelheim. V. Gounant declares consulting fees from AstraZeneca, Bristol Myers Squibb, Janssen, Pfizer, Sanofi, Takeda and Roche; and support for attending meetings and/or travel from Janssen, Pfizer, Sanofi, Takeda and Roche. The remaining authors have no conflicts of interest to declare.
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources